European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Meta Expands AI Training With Employee Activity Tracking Tools 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
EMERYVILLE, Calif., March 10, 2017 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted a new employee a stock option to purchase 26,250 shares of the company’s common stock, at a per share exercise price of $16.97, the closing trading price on March 7, 2017, and restricted stock units to acquire 4,375 shares of the company’s common stock. The stock option and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
About Adamas Pharmaceuticals, Inc.
Adamas develops new medicines to improve the daily lives of those affected by chronic neurologic disorders, including Parkinson’s disease, multiple sclerosis, epilepsy and Alzheimer’s disease. Adamas has pioneered a platform to develop medicines, called chrono-synchronous therapies, for chronic neurologic disorders based on an understanding of the time-dependent biologic processes responsible for disease activity and drug response to potentially achieve symptomatic relief without tolerability issues. The company’s most advanced product candidate, ADS-5102, is in development for levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease and walking impairment. An NDA supporting ADS-5102 for the treatment of LID in patients with Parkinson’s disease is under review by the FDA, with a PDUFA date of August 24, 2017. Adamas is exploring other indications for ADS-5102 for further development. Adamas is also investigating ADS-4101 for the treatment of partial onset seizures in patients with epilepsy. Additionally, Adamas’ licensed assets, NAMENDA XR® and NAMZARIC®, are currently marketed by Allergan, and Adamas is eligible to receive royalties on sales of these medicines beginning in June 2018 and May 2020, respectively. For more information, please visit www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are trademarks of Merz Pharma GmbH & Co. KGaA.
Martin Forrest Vice President, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. 510-450-3528 [email protected]
